Skip to main content
Top

11-09-2024 | Asthma Attack | News

ERS 2024

Depemokimab: a novel, long-acting biological in severe asthma

MedNet.nl: Depemokimab is a new, long-acting biological drug for the treatment of severe eosinophilic asthma. The phase III studies SWIFT-I and SWIFT-II show that this drug leads to a reduction of 58 and 48% respectively in the annual number of exacerbations. 

Related topics

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now
Video
SPONSORED

Targeting COPD with type 2 inflammation: emerging biologic landscape

1.5 European CME credits (ECMEC®s)

Watch an insightful session tailored for pulmonologists and healthcare professionals eager to enhance their understanding of COPD and the latest advances in biologic therapies.

Sponsored by:
  • Sanofi
Developed by: Springer Healthcare
Watch now
Video